Online inquiry

IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9444MR)

This product GTTS-WQ9444MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets KIR3DL2 gene. The antibody can be applied in Lymphoma, cutaneous T cell (CTCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001242867.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3812
UniProt ID P43630
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9444MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7097MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ6173MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CP-751871
GTTS-WQ12998MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ10603MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY3300054
GTTS-WQ15786MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ15966MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ10746MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ12844MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ONC-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW